RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19
ID: RRPV-24-02-OralVxType: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEBARDA - ASPR / DAAPPO / BARDA DCMAWASHINGTON, DC, 20515, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH (AN42)

Original Source

https://sam.gov/opp/bf804956c307429184c75fae84af5618/view
Timeline
    Description

    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals for the "NextGen Oral Formulation Vaccines for COVID-19" under the Rapid Response Partnership Vehicle (RRPV) Consortium. The objective of this initiative is to advance oral vaccine platforms and technologies into a proof-of-concept Phase 1 clinical trial, enhancing understanding of their potential and improving COVID-19 solutions to bolster preparedness against future health security threats. This effort is critical in the ongoing response to the COVID-19 pandemic and aims to develop innovative vaccine solutions. Interested parties should note that the proposal submission deadline has been extended to November 15, 2024, and can contact Rebecca Harmon at rebecca.harmon@ati.org for further information.

    Point(s) of Contact
    Rebecca Harmon
    rebecca.harmon@ati.org
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19
    Currently viewing
    Special Notice
    Similar Opportunities
    Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking proposals for the "Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability" through a Special Notice. The objective of this procurement is to establish a long-term partnership focused on developing a flexible and rapid response capability for vaccine development against pandemic influenza and other priority pathogens, initially emphasizing influenza mRNA vaccine development. This initiative is critical for enhancing the nation's preparedness and response to emerging infectious diseases, ensuring readiness to pivot quickly in the face of public health threats. Interested parties can access the full Request for Project Proposals and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.
    Decentralized Clinical Operations for Healthcare and Research (D-COHRe) Partnership Solicitation
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking proposals for the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) Partnership Solicitation, aimed at establishing partnerships with organizations that provide decentralized healthcare services or have decentralized clinical research capabilities. The initiative focuses on enhancing clinical trial capabilities and medical countermeasure (MCM) development, particularly during public health emergencies, by building a sustainable decentralized clinical research infrastructure. With an anticipated funding amount of up to $100 million distributed over a five-year performance period, proposals are due by December 9, 2024, at 12:00 PM EST. Interested parties can direct inquiries to LaunchOfficeContracting@hhs.gov for proposal submissions and additional information.
    Marburg virus (MARV) and Sudan virus (SUDV) Vaccines
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Biomedical Advanced Research and Development Authority (BARDA), is seeking information from potential partners regarding the development of vaccines for the Marburg virus (MARV) and Sudan virus (SUDV). This Sources Sought Notice (SSN) aims to gather insights on vaccine candidates, particularly those that are in or beyond Phase 2 clinical trials, to enhance BARDA's understanding of the current marketplace for these critical medical countermeasures. The development of effective vaccines against MARV and SUDV is vital for preparing for potential public health crises stemming from emerging infectious diseases. Interested parties are encouraged to submit concise responses, limited to ten pages, by November 18, 2024, and can direct inquiries to primary contact Yifan Yang at yifan.yang@hhs.gov or secondary contact Greg Smith at greg.smith1@hhs.gov.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Office of Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative medical countermeasures (MCMs) to address public health emergencies. The initiative invites submissions across various Areas of Interest (AOIs), including but not limited to vaccine development, diagnostics, and therapeutics for infectious diseases and chemical threats. This program is crucial for enhancing the nation's preparedness against health security threats, particularly in light of recent global health challenges. Interested parties must register on SAM.gov and adhere to specific submission deadlines, with multiple awards anticipated based on scientific merit and funding availability. For further inquiries, respondents can contact Aarati Singal or Lara Emmons at DRIVeAcquisitions@hhs.gov.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 NIAID DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing medical countermeasures against infectious diseases. This opportunity encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant pathogens, and the creation of direct acting antivirals targeting viruses with pandemic potential. The initiative is critical for enhancing public health responses to emerging infectious threats and includes funding estimates of up to $8.5 million for Research Area 001 and $20 million for Research Area 002, with proposals due to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) platform, starting around November 22, 2024. For further inquiries, interested parties may contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov.
    BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is issuing a Sources Sought Notice to gather information on antibiotics in development for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and bloodstream infections (BSI) caused by drug-resistant bacteria. This initiative aims to enhance understanding of the antibiotic development landscape and prepare for future procurement to strengthen U.S. emergency response capabilities against CBRN threats and antibiotic resistance. BARDA is particularly interested in details regarding antibiotic candidates, including their clinical indications, development status, manufacturing plans, and commercialization strategies, with submissions due by November 29, 2025. Interested parties should contact Erin Greninger at erin.greninger@hhs.gov or Audrey Glover at audrey.glover@hhs.gov for further information.
    Pediatric Flu Vaccine – 2025-2026
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is seeking proposals for the procurement of pediatric influenza vaccines for the 2025-2026 season under solicitation number 75D301-25-R-73215. The CDC requires one or more indefinite quantity, indefinite delivery contracts for the purchase of vaccines specifically for children aged 0 through 18 years, with a minimum order size of 100 doses and a maximum of 30 million doses, to support immunization programs under the Vaccine for Children (VFC) program. This initiative is crucial for enhancing public health by ensuring the availability of quality vaccines to reduce healthcare costs associated with preventable diseases. Proposals are due by November 12, 2024, and interested parties should direct inquiries to Matheu Wilson at zlb4@cdc.gov or David Dombeck at vwj8@cdc.gov.
    Adult Flu Vaccines 2025-2026
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is soliciting proposals for Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts to procure adult influenza vaccines for the 2025-2026 season. The procurement aims to utilize Section 317 vaccine purchase funds to provide state and local health departments with access to vaccines at favorable prices, particularly targeting populations at higher risk of under-vaccination. This initiative includes a minimum order of 100 doses and a maximum of 6 million doses, with strict compliance to FDA standards and specific delivery requirements. Proposals are due by November 12, 2024, and interested parties should direct inquiries to Matheu Wilson at zlb4@cdc.gov or David Dombeck at vwj8@cdc.gov. The contract period will extend from the date of award through February 28, 2026.
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Active
    Health And Human Services, Department Of
    Solicitation HEALTH AND HUMAN SERVICES, DEPARTMENT OF Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) is seeking proposals for various health research and development services. This opportunity is typically used for experimental development and healthcare services. The place of performance is in the USA. For more information, please contact BARDA-BAA@hhs.gov. The deadline for proposal submission is September 25, 2028, at 4:30 PM Eastern Time.
    Office-Wide Innovative Solutions Opening for Resilient Systems Office (RSO)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting innovative solutions aimed at enhancing the resilience of healthcare systems via its Resilient Systems Office (RSO). This opportunity invites submissions from eligible entities, including universities, nonprofits, and small businesses, to address systemic challenges in healthcare and public health by leveraging cutting-edge technologies that improve care quality and availability. The solicitation emphasizes the importance of sociotechnical system innovations and adaptive solutions that enhance the reliability and interoperability of health ecosystems. Interested parties must submit solution summaries for feedback before full proposal submissions, with the solicitation open until March 3, 2029. For further inquiries, submissions should be directed to the designated online platforms, and the primary contact email is provided in the solicitation details.